Metastatic breast cancer trials recruiting in Michigan

All Metastatic breast cancer trials nationally

Cities in Michigan

Recruiting trials in Michigan

• A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
  NCT07227831 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years and older · Sex: All (male and female) · Michigan: Bay City, Clarkston, Detroit, Flint
• A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
  NCT05894239 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Detroit
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Detroit
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
  NCT05696626 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Grand Rapids
• Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
  NCT05455619 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ypsilanti
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
  NCT06784193 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Grand Rapids
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
  NCT05573126 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · Michigan: Detroit
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Detroit
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor, Royal Oak